Research and development of major new antiviral drugs for chronic hepatitis B
10.3760/cma.j.issn.1674-2397.2024.04.003
- VernacularTitle:慢性乙型肝炎主要抗病毒新药研发现状
- Author:
Yilin MA
1
Author Information
1. 浙江大学医学院附属第一医院感染病科 传染病重症诊治全国重点实验室 国家感染性疾病临床医学研究中心，杭州 310003
- Keywords:
Chronic hepatitis B;
Antiviral drugs;
Small molecule drugs;
Immune regulatory inhibitors;
Research status
- From:
Chinese Journal of Clinical Infectious Diseases
2024;17(4):263-282
- CountryChina
- Language:Chinese
-
Abstract:
Viral hepatitis B is one of the most widespread and harmful infectious diseases in China，and also is a worldwide disease burden seriously threatening human health. According to data released by the Polaris Observatory Collaborators，in China there were 79.74 million people infected with hepatitis B virus in 2022. In the past two years，the research and development of new drugs has advanced rapidly. A variety of new anti-hepatitis B treatment small molecule drugs and immunomodulatory inhibitors are entering the clinical trial stage. This article reviews the progress on the research and development of major new antiviral drugs for chronic hepatitis B in recent years，and proposes strategies of clinical cure or complete cure for chronic hepatitis B.
